Evidence that multiple defects in lipid regulation occur before hyperglycemia during the prodrome of type-2 diabetes

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Anderson, Simon G ^a   Dunn, Warwick B ^a,b   Banerjee, Moulinath ^a   Brown, Marie ^a   Broadhurst, David I ^a,c   Goodacre, Royston ^a   Cooper, Garth J S ^a,d,e   Kell, Douglas B ^a   Cruickshank, J Kennedy ^a,f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; ADIPONECTIN; DIACYLGLYCEROL; GLUCOSE; HEMOGLOBIN A1C; LONG CHAIN FATTY ACID; PHOSPHOLIPID; SHORT CHAIN FATTY ACID; CARNITINE; GLUCOSE BLOOD LEVEL; INSULIN;

ADIPOCYTE; ADULT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; FATTY ACID OXIDATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; LIPID METABOLISM; LIPID STORAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PREGNANCY DIABETES MELLITUS; PRINCIPAL COMPONENT ANALYSIS; RISK FACTOR; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WAIST CIRCUMFERENCE; ADIPOSE TISSUE; ANALOGS AND DERIVATIVES; BLOOD; DIET RESTRICTION; GLUCOSE TOLERANCE TEST; IMPAIRED GLUCOSE TOLERANCE; METABOLISM; METABOLOME; PATHOLOGY; PREGNANCY;

ADIPONECTIN; ADIPOSE TISSUE; ADULT; BLOOD GLUCOSE; CARNITINE; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; DIGLYCERIDES; FASTING; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; INSULIN; LIPID METABOLISM; METABOLOME; PHOSPHOLIPIDS; PREDIABETIC STATE; PREGNANCY; PRINCIPAL COMPONENT ANALYSIS;

EID: 84906967703     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103217     Document Type: Article

References (90)

1. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, et al. (2002) Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 106: 2085-2090.
2. Meigs JB, O'Donnell C J, Tofler GH, Benjamin EJ, Fox CS, et al. (2006) Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 55: 530-537.
3. Banerjee M, Anderson SG, Malik RA, Austin CE, Cruickshank JK (2012) Small artery function 2 years postpartum in women with altered glycaemic distributions in their preceding pregnancy. Clin Sci (Lond) 122: 53-61.
4. Schofield I, Malik R, Izzard A, Austin C, Heagerty A (2002) Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 106: 3037-3043.
5. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, et al. (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-2559.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577-1589.
7. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, et al. (2011) Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343: d6898.
8. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, et al. (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369: 1317-1326.
9. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317: 703-713.
10. Mohamed Q, Gillies MC, Wong TY (2007) Management of diabetic retinopathy: a systematic review. JAMA 298: 902-916.
11. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR (2008) Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359: 1565-1576.
12. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, et al. (2010) Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376: 419-430.
13. Halcox JP, Deanfield JE (2004) Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 109: II42-48.
14. Undas A, Brozek J, Musial J (2002) Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease. Clin Lab 48: 287-296.
15. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364: 685-696.
16. Heart Protection Study Collaborative Group, Bulbulia R, Bowman L, Wallendszus K, Parish S, et al. (2011) Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 378: 2013-2020.
17. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, et al. (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305: 2556-2564.
18. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375: 735-742.
19. Zaharan NL, Williams D, Bennett K (2013) Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol 75: 1118-1124.
20. Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, et al. (2009) Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 119: 1661-1670.
21. Cooper GJ (2012) Selective divalent copper chelation for the treatment of diabetes mellitus. Curr Med Chem 19: 2828-2860.
22. Kell DB (2009) Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2: 2.
23. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL (2011) Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev 40: 387-426.
24. Dunn WB, Goodacre R, Neyses L, Mamas M (2011) Integration of metabolomics in heart disease and diabetes research: current achievements and future outlook. Bioanalysis 3: 2205-2222.
25. Griffin JL, Atherton H, Shockcor J, Atzori L (2011) Metabolomics as a tool for cardiac research. Nat Rev Cardiol 8: 630-643.
26. Barallobre-Barreiro J, Chung YL, Mayr M (2013) Proteomics and metabolomics for mechanistic insights and biomarker discovery in cardiovascular disease. Rev Esp Cardiol 66: 657-661.
27. Floegel A, Stefan N, Yu Z, Muhlenbruch K, Drogan D, et al. (2013) Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 62: 639-648.
28. Hedderson MM, Darbinian J, Havel PJ, Quesenberry CP, Sridhar S, et al. (2013) Low Prepregnancy Adiponectin Concentrations Are Associated With a Marked Increase in Risk for Development of Gestational Diabetes Mellitus. Diabetes Care.
29. Kim OY, Lee JH, Sweeney G (2013) Metabolomic profiling as a useful tool for diagnosis and treatment of chronic disease: focus on obesity, diabetes and cardiovascular diseases. Expert Rev Cardiovasc Ther 11: 61-68.
30. Dunn W, Broadhurst D, Deepak S, Buch M, McDowell G, et al. (2007) Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate. Metabolomics 3: 413-426.
31. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, et al. (2005) Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112: 3868-3875.
32. Turer AT, Stevens RD, Bain JR, Muehlbauer MJ, van der Westhuizen J, et al. (2009) Metabolomic Profiling Reveals Distinct Patterns of Myocardial Substrate Use in Humans With Coronary Artery Disease or Left Ventricular Dysfunction During Surgical Ischemia/Reperfusion. Circulation 119: 1736-1746.
33. Lewis GD, Wei R, Liu E, Yang E, Shi X, et al. (2008) Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 118: 3503-3512.
34. Kenny LC, Broadhurst DI, Dunn W, Brown M, North RA, et al. (2010) Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension 56: 741-749.
35. Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, et al. (2010) alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One 5: e10883.
36. Griffin JL, Nicholls AW (2006) Metabolomics as a functional genomic tool for understanding lipid dysfunction in diabetes, obesity and related disorders. Pharmacogenomics 7: 1095-1107.
37. Oresic M, Simell S, Sysi-Aho M, Nanto-Salonen K, Seppanen-Laakso T, et al. (2008) Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 205: 2975-2984.
38. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, et al. (2011) Metabolite profiles and the risk of developing diabetes. Nat Med 17: 448-453.
39. Bao YQ (2009) Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers. J Proteome Res 8: 1623-1630.
40. Li X, Xu Z, Lu X, Yang X, Yin P, et al. (2009) Comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry for metabonomics: Biomarker discovery for diabetes mellitus. Anal Chim Acta 633: 257-262.
41. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, et al. (2008) Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 7: 45-56.
42. Bellamy L, Casas JP, Hingorani AD, Williams D (2009) Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 373: 1773-1779.
43. Ratner RE (2007) Prevention of type 2 diabetes in women with previous gestational diabetes. Diabetes Care 30 Suppl 2: S242-245.
44. Kell DB, Oliver SG (2004) Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. Bioessays 26: 99-105.
45. Hapo Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, et al. (2008) Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358: 1991-2002.
46. WHO Expert Committee on Physical Status (1995) Physical Status: the Use and Interpretation of Anthropometry. Geneva: WHO.
47. Zelena E, Dunn WB, Broadhurst D, Francis-McIntyre S, Carroll KM, et al. (2009) Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Anal Chem 81: 1357-1364.
48. Dunn WB, Broadhurst D, Brown M, Baker PN, Redman CW, et al. (2008) Metabolic profiling of serum using Ultra Performance Liquid Chromatography and the LTQ-Orbitrap mass spectrometry system. J Chromatogr B Analyt Technol Biomed Life Sci 871: 288-298.
49. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, et al. (2011) Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 6: 1060-1083.
50. Brown M, Wedge DC, Goodacre R, Kell DB, Baker PN, et al. (2011) Automated workflows for accurate mass-based putative metabolite identification in LC/MS-derived metabolomic datasets. Bioinformatics 27: 1108-1112.
51. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, et al. (2007) Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics 3: 211-221.
52. Berger K, Winzell MS, Mei J, Erlanson-Albertsson C (2004) Enterostatin and its target mechanisms during regulation of fat intake. Physiol Behav 83: 623-630.
53. Kelly A, Stanley CA (2001) Disorders of glutamate metabolism. Ment Retard Dev Disabil Res Rev 7: 287-295.
54. Halamkova L, Mailloux S, Halamek J, Cooper AJ, Katz E (2012) Enzymatic analysis of alpha-ketoglutaramate - a biomarker for hyperammonemia. Talanta 100: 7-11.
55. Nakashima Y, Fujii H, Sumiyoshi S, Wight TN, Sueishi K (2007) Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol 27: 1159-1165.
56. Aitken JF, Loomes KM, Scott DW, Reddy S, Phillips AR, et al. (2010) Tetracycline treatment retards the onset and slows the progression of diabetes in human amylin/islet amyloid polypeptide transgenic mice. Diabetes 59: 161-171.
57. McGarry JD (1998) Glucose-fatty acid interactions in health and disease. Am J Clin Nutr 67: 500S-504S.
58. Wang Y, Xu A, Knight C, Xu LY, Cooper GJ (2002) Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem 277: 19521-19529.
59. Selvin E, Najjar SS, Cornish TC, Halushka MK (2010) A comprehensive histopathological evaluation of vascular medial fibrosis: insights into the pathophysiology of arterial stiffening. Atherosclerosis 208: 69-74.
60. Bjorklund A, Yaney G, McGarry JD, Weir G (1997) Fatty acids and beta-cell function. Diabetologia 40 Suppl 3: B21-26.
61. Afkhami-Ardekani M, Rashidi M (2009) Iron status in women with and without gestational diabetes mellitus. J Diabetes Complications 23: 194-198.
62. Bo S, Menato G, Villois P, Gambino R, Cassader M, et al. (2009) Iron supplementation and gestational diabetes in midpregnancy. Am J Obstet Gynecol 201: 158 e151-156.
63. Qiu C, Zhang C, Gelaye B, Enquobahrie DA, Frederick IO, et al. (2011) Gestational diabetes mellitus in relation to maternal dietary heme iron and nonheme iron intake. Diabetes Care 34: 1564-1569.
64. Aregbesola A, Voutilainen S, Virtanen JK, Mursu J, Tuomainen TP (2013) Body iron stores and the risk of type 2 diabetes in middle-aged men. Eur J Endocrinol 169: 247-253.
65. Bao W, Rong Y, Rong S, Liu L (2012) Dietary iron intake, body iron stores, and the risk of type 2 diabetes: a systematic review and meta-analysis. BMC Med 10: 119.
66. Huang J, Jones D, Luo B, Sanderson M, Soto J, et al. (2011) Iron overload and diabetes risk: a shift from glucose to Fatty Acid oxidation and increased hepatic glucose production in a mouse model of hereditary hemochromatosis. Diabetes 60: 80-87.
67. Swaminathan S, Fonseca VA, Alam MG, Shah SV (2007) The role of iron in diabetes and its complications. Diabetes Care 30: 1926-1933.
68. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, et al. (2011) Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123: 2292-2333.
69. Anderson SG, Hutchings DC, Heald AH, Anderson CD, Sanders TA, et al. (2014) Haemostatic factors, lipoproteins and long-term mortality in a multi-ethnic population of Gujarati, African-Caribbean and European origin. Atherosclerosis 236: 62-72.
70. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, et al. (2003) Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107: 1733-1737.
71. Miyazawa T, Ibusuki D, Yamashita S, Nakagawa K (2008) Analysis of amadoriglycated phosphatidylethanolamine in the plasma of healthy subjects and diabetic patients by liquid chromatography-tandem mass spectrometry. Ann N Y Acad Sci 1126: 291-294.
72. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, et al. (2002) A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem 277: 38517-38523.
73. White DL, Collinson A (2013) Red meat, dietary heme iron, and risk of type 2 diabetes: the involvement of advanced lipoxidation endproducts. Adv Nutr 4: 403-411.
74. Zacharski LR, DePalma RG, Shamayeva G, Chow BK (2013) The statin-iron nexus: anti-inflammatory intervention for arterial disease prevention. Am J - Public Health 103: e105-112.
75. Roehrich ME, Mooser V, Lenain V, Herz J, Nimpf J, et al. (2003) Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem 278: 18368-18375.
76. Wong G, Barlow CK, Weir JM, Jowett JB, Magliano DJ, et al. (2013) Inclusion of plasma lipid species improves classification of individuals at risk of type 2 diabetes. PLoS One 8: e76577.
77. Lenz ML, Hughes H, Mitchell JR, Via DP, Guyton JR, et al. (1990) Lipid hydroperoxy and hydroxy derivatives in copper-catalyzed oxidation of low density lipoprotein. J Lipid Res 31: 1043-1050.
78. Cooper GJ, Chan YK, Dissanayake AM, Leahy FE, Keogh GF, et al. (2005) Demonstration of a hyperglycemia-driven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation: quantitative comparisons between the biology of copper and eight other nutritionally essential elements in normal and diabetic individuals. Diabetes 54: 1468-1476.
79. Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, et al. (2012) Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 8: 615.
80. Jullig M, Chen X, Hickey AJ, Crossman DJ, Xu A, et al. (2007) Reversal of diabetes-evoked changes in mitochondrial protein expression of cardiac left ventricle by treatment with a copper(II)-selective chelator. Proteomics Clin Appl 1: 387-399.
81. Jullig M, Hickey AJ, Middleditch MJ, Crossman DJ, Lee SC, et al. (2007) Characterization of proteomic changes in cardiac mitochondria in streptozotocin-diabetic rats using iTRAQ isobaric tags. Proteomics Clin Appl 1: 565-576.
82. Randle PJ, Garland PB, Hales CN, Newsholme EA (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785-789.
83. Assimacopoulos-Jeannet F, Thumelin S, Roche E, Esser V, McGarry JD, et al. (1997) Fatty acids rapidly induce the carnitine palmitoyltransferase I gene in the pancreatic beta-cell line INS-1. J Biol Chem 272: 1659-1664.
84. Bentley R (1990) The shikimate pathway - a metabolic tree with many branches. Crit Rev Biochem Mol Biol 25: 307-384.
85. Bansal N, Anderson SG, Vyas A, Gemmell I, Charlton-Menys V, et al. (2011) Adiponectin and lipid profiles compared with insulins in relation to early growth of British South Asian and European children: the Manchester children's growth and vascular health study. J Clin Endocrinol Metab 96: 2567-2574.
86. Arner P (2005) Insulin resistance in type 2 diabetes - role of the adipokines. Curr Mol Med 5: 333-339.
87. Li S, Shin HJ, Ding EL, van Dam RM (2009) Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302: 179-188.
88. Wlazlo N, van Greevenbroek MM, Ferreira I, Jansen EH, Feskens EJ, et al. (2013) Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study. Diabetes Care 36: 309-315.
89. Wang Y, Lam KS, Chan L, Chan KW, Lam JB, et al. (2006) Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem 281: 16391-16400.
90. Meikle PJ, Wong G, Barlow CK, Kingwell BA (2014) Lipidomics: potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease. Pharmacol Ther 143: 12-23.